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INTRODUCTION
Allogeneic bone marrow transplant (BMT) remains the
only definitive cure for chronic myeloid leukemia (CML).
H o w e v e r, the effectiveness of allogeneic BMT is limited by
donor availability and the toxicity of graft-vs.-host disease
(GVHD), especially in older patients [1]. Autologous BMT
avoids these obstacles, but has not been curative in CML
even though it may prolong survival [2–8]. Genetic marking
studies demonstrate that reinfusion of clonogenic Philadel-
phia (Ph)1 p rogenitor cells contaminating the autologous
graft contributes to relapse of CML after autologous BMT
[9]. More o v e r, the BMT preparative regimen alone is usually
i n s u fficient to completely eradicate CML, as demonstrated
by the high relapse rates associated with syngeneic and
T cell–depleted allogeneic BMT [10]. Antileukemic activity
mediated by allogeneic T cells is crucial to the cure of CML
because of the relative resistance of CML progenitors to
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ABSTRACT
Autologous bone marrow transplantation (BMT) has not been curative in chronic myeloid leukemia (CML),
because of the inability to purge CML from the autograft and the absence of the allogeneic T cell–mediated
antileukemic activity. However, recent advances demonstrate that normal progenitors can be selected from CML
m a rrows by a variety of techniques, including isolation by their small size. Furt h e rm o re, we found that myeloid
g rowth factors have a potent antileukemic effect against CML pro g e n i t o r s in vitro by inducing their terminal diff e r-
entiation. Based on these data, we initiated a trial of autologous BMT in patients with high-risk CML. Autografts
w e re processed in an attempt to enrich for normal progenitors, first by isolating small cells by counterflow centrifu-
gal elutriation and then incubating them in granulocyte-macrophage colony-stimulating factor (GM-CSF) for 72
hours. After a conditioning regimen of busulfan and cyclophosphamide, all patients received GM-CSF daily for 2
months. The median age of the 13 patients in the trial was 45 years (range 17–56 years). The median duration of
disease before BMT was 24 months (range 13–72 months). Eight patients were in chronic phase (CP), and five were
in accelerated phase (AP). All patients failed to achieve a cytogenetic response to interf e ro n -a and were 100%
Philadelphia chromosome (Ph)1 b e f o re BMT. There were three transplant-related deaths, all AP patients. All of the
remaining 10 patients engrafted with some degree of Ph– hematopoiesis; despite high-risk features, nine patients
engrafted 100% Ph–. All patients relapsed cytogenetically at a median of 6 months (range 4–22 months). These
results demonstrate that autologous BMT can consistently induce complete Ph– engraftment in CP patients. GM-
CSF appears to produce a clinical antileukemic effect against CML after autologous BMT.
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s t a n d a rd cytotoxic agents [11,12], further demonstrated by
the ability of donor leukocyte infusions to salvage CML
patients who relapse after allogeneic BMT [13–15]. Thus,
for autologous BMT to be successful in CML, both method-
ology that can eliminate or “purge” CML progenitors fro m
the autograft and systemic antileukemic activity beyond that
p rovided by the cytotoxic preparative regimen are needed. 
N o rmal hematopoietic stem cells persist in the bone
marrow of most CML patients, at least early in the disease,
as evidenced by the ability to induce cytogenetic remissions
with chemotherapy [16] or interf e ron [17] in some CML
patients. Moreover, normal polyclonal hematopoiesis can be
re s t o red in vitro in long-term marrow cultures of CML
bone marrow [18]. Normal progenitors can now be isolated
f rom CML marrows by a variety of techniques, including
their identification by absence of class II histocompatibility
antigens [19] and their small size [20]. We [21] and others
[22] previously found that myeloid growth factors will
induce terminal diff e rentiation of CML cells at doses that
p roduce optimal growth of normal hematopoietic pro-
genitors. Using clinical marrow processing in an attempt to
enrich CML autografts for normal progenitors combined
with myeloid growth factors as systemic antileukemic activ-
ity beyond the preparative regimen, we initiated a trial of
autologous BMT in high-risk CML patients. 
MATERIALS AND METHODS 
Patients 
The diagnosis of CML re q u i red the presence of the
BCR-ABL fusion gene by karyotypic analysis, fluorescence
in situ hybridization (FISH), and/or molecular analysis
(recombinant DNA analysis of the BCR-ABL fusion gene or
polymerase chain reaction detection of the BCR-ABL
hybrid mRNA). Patients in accelerated phase (AP) were eli-
gible. The diagnosis of AP was based on the following:
$10% but ,30% blasts in the blood or bone marro w,
e x t r a m e d u l l a ry disease, .10% basophilia in the blood or
bone marrow, other cytogenetic abnormalities in addition to
a single Ph, or uncontrollable leukocytosis. Patients in
c h ronic phase (CP) were eligible only if they failed to
achieve a cytogenetic remission on a trial of interferon. Fail-
ure to achieve cytogenetic remission was defined as the lack
of a hematologic response after 4 months or any Ph–
metaphases after 6 months of interf e ron therapy. This
p rotocol was reviewed and approved by the institutional
i n t e rnal review boards of the Johns Hopkins Medical Institu-
tions and the University of Colorado. Informed written con-
sent for study participation was obtained from all patients. 
A u t o graft manipulation
Autologous marrow was harvested before beginning
p reparative chemotherapy. A small cell fraction was isolated
f rom the bone marrow by counterflow centrifugal elutriation
(CCE) [23,24]. Autologous graft mononuclear cells, isolated
by standard apheresis techniques, were loaded into a Beck-
man JE-5.0 elutriation rotor and chamber (Beckman Instru-
ments, Palo Alto, CA) at a total flow rate of 50 m L / m i n ,
rotor speed of 3000 rpm, and temperature of 20°C. With the
rotor speed held constant, the rate of media flow was raised
i n c rementally to separate the three small cell fractions
( re c o v e red at a flow rate of 50, 110, and 140 mL/min) fro m
the large cell fraction re c o v e red after shutting off the ro t o r.
The three small cell fractions were combined and re s u s-
pended at 331 06  cells/mL in X-VIVO 10 Media
( B i o W h i t a k e r, Walkersville, MD) containing 10% autolo-
gous marrow plasma supplemented with 100 units/mL of
recombinant human granulocyte-macrophage colony-stimu-
lating factor (GM-CSF; Immunex, Seattle, WA). After incu-
bation in 1000 mL Fenwall tissue culture bags for 3 days at
37°C in a 5% CO2 h u m i d i fied incubator, the small cell frac-
tion was cry o p res e rved in dimethyl sulfoxide. Kary o t y p i c
analysis was p e rf o rmed on the small cell fraction before
and after the 72-hour GM-CSF incubation. The large cell
fraction was also cry o p re s e rved as a “back-up” marro w, to be
infused if there was no evidence of engraftment by peripheral
cell count and bone marrow examination by day 50 after
B M T. This large cell fraction is used for clinical T- c e l l
depletion, and produces full donor engraftment [23,24].
Treatment protocol 
All patients received busulfan at 1 mg/kg ideal body
weight (IBW) orally every 6 hours for 16 doses on days –9,
–8, –7, and –6. Dose adjustment was made at the time of the
fifth dose based on first-dose pharmacokinetics [25]. This
was followed by cyclophosphamide 50 mg/kg IBW/dintra-
venously on days –5, –4, –3, and –2 with marrow rescue on
day 0, about 48 hours after the final dose of cyclophos-
phamide. Forced diuresis or Mesna was used to pre v e n t
cyclophosphamide-induced bladder toxicity. Patients
seropositive for herpes simplex received valacyclovir 500 mg
orally three times a day from day –2 through day 30. Broad-
spectrum antibiotics were given empirically for fever during
aplasia, and amphotericin B was added for documented sys-
temic fungal infections or for persistent fever unresponsive
to antibiotic therapy. Platelet transfusions were given for
platelet counts below 20,000/mm3. Hematocrits were main-
tained above 25% by packed red cell transfusions. 
All patients received recombinant human GM-CSF
(Immunex) dosed at 250 mg / m2/d as a subcutaneous injec-
tion, beginning day 5 after BMT and continuing until
the absolute neutrophil count (ANC) was .2 0 0 0 / m m3 f o r
3 consecutive days. The GM-CSF dose was then re d u c e d
to 125 mg / m2/d and continued until 60 days after BMT.
B e f o re an ANC .2 0 0 0 / m m3, patients experiencing grade
III toxicity thought to be related to GM-CSF had a 50%
dose reduction. If the ANC was .2 0 , 0 0 0 / m m3, the GM-
CSF was interrupted and reinstated at 125 mg/m2/d follow-
ing the re t u rn of ANC levels to #1 0 , 0 0 0 / m m3. After the
completion of GM-CSF dosing on day 60, patients were
o b s e rved off all antileukemic therapy, including interf e ro n .
Cytogenetic and molecular analysis for the Ph was per-
f o rmed at initial engraftment and every 3 months for 1 year
after BMT. Treatment with GM-CSF or interferon was rec-
ommended at the time of relapse. 
Statistics 
Data on engraftment, relapse (molecular/cytogenetic
and hematologic), and disease-free and overall survival were
acquired concurrently. Pearson’s correlation coefficient was
used to calculate the effect of various patient factors (dura-
tion of disease, interf e ron use, hydro x y u rea use, and graft
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composition) on engraftment and time to relapse. Relapse
after BMT was defined as any Ph1 cells detectable by FISH
or metaphase analysis or evidence of the BCR-ABL fusion
gene by molecular analysis. Hematologic remission was
defined as peripheral white blood cell counts less than
103103/mm3 with no immature forms (i.e., blasts, promye-
locytes, myelocytes, or metamyelocytes) on the diff e re n t i a l
cell count, and the disappearance of all clinical symptoms
and signs of disease including palpable splenomegaly. 
RESULTS
F rom May 1996 through Febru a ry 1998, 13 CML
patients (eight males and five females) who met the eligibility
criteria entered this trial (Table 1). Patient 10 received tre a t-
ment at the University of Colorado; all other part i c i p a n t s
received treatment at Johns Hopkins. Median age was 45
years (range 17–56 years). Median duration of disease before
BMT was 24 months (range 13–72 months). All patients
failed a trial of interf e ro n -a, which was intended to induce a
cytogenetic response: three of the 13 failed to achieve hema-
tologic remission and the other 10 had no cytogenetic
response to at least 6 months of interf e ron (Table 1). Nine
patients also received hydro x y u rea for a median of 7 months
(range 1–40 months) and one patient received 7 months of
busulfan before BMT. Eight patients were in CP and five
w e re in AP. 
At the time of BMT, the bone marrow from all patients
was 100% Ph1. A median of 1.231 08 (range 0.74–1.9331 08)
mononuclear marrow cells/kg was loaded into the elutriator.
The autograft (the CCE small cell fraction) was 34 6 2% of
the marrow mononuclear cells, and the large cell fraction,
c ry o p re s e rved as a “back-up” marro w, was 32 6 1%. After
the 72-hour in vitro c u l t u re in GM-CSF, the median cell
re c o v e ry was 72% (range 54–94%). The transplanted auto-
graft contained a median of 131 06 (range 0.4–9.831 06)
C D 3 41 cells/kg, a median re c o v e ry of 68% (range 25–123%)
after in vitro c u l t u re in GM-CSF. The autografts contained a
median of 0.831 05 (range 0.01–531 05) colony-form i n g
unit (CFU)-GM/kg, a 90% (range 68–131%) re c o v e ry after
in vitro c u l t u re. Cytogenetics on the isolated small cell frac-
tion after in vitro incubation in GM-CSF was perf o rm e d
in 10 patients. Only three of these patients (patients 8, 9, and
11) demonstrated any Ph– metaphases in the treated small
cell graft, and this population was small (10–20%). 
T h e re were three transplant-related deaths, all AP
patients: two patients (patients 3 and 7) failed to engraft and
died on days 134 and 72, re s p e c t i v e l y, and patient 5 died of
veno-occlusive disease of the liver on day 15. Patient 3
received the large-cell, “back-up” marrow on day 64, but died
70 days later without evidence of engraftment. All re m a i n i n g
10 patients engrafted with some degree of Ph– h e m a t o p o i e s i s ;
nine were 100% Ph– at initial engraftment (Table 2). Reverse
transcriptase polymerase chain reaction analysis for BCR-
ABL mRNA also eventually became negative after BMT in
eight of the nine patients. Engraftment occurred at a median
of 31 days (range 19–180 days) to an ANC $5 0 0 / m m3 and a
median of 81 days (range 22–210 days) to platelet transfusion
independence (Table 2). Disease duration (r 5 0.63, p 5 0 . 0 3 ,
P e a r s o n ’s correlation coefficient), but not duration of inter-
f e ro n -a (r 5 0.12, p 5 0.72) or hydro x y u rea therapy (r 5
0.46, p 5 0.12) or number of transplanted CD341 c e l l s / k g
(r 5 0.28, p 5 0.4) had an impact on time to engraftment. In
fact, the number of CD341 cells/kg infused (0.9831 06 a n d
1 . 131 06, respectively) for the two patients who failed to
achieve engraftment was equal to the median number infused
for the whole group. 
Grade III toxicities (National Cancer Institute Common
Toxicity Criteria) were seen in two patients, fever in one and
capillary leak syndrome in the other, requiring a 50% reduc-
tion in the GM-CSF dose. There were no other grade III or
IV toxicities requiring dose modifications.
All patients had a cytogenetic relapse at a median of
6 months (range 4–22 months) (Table 2). The longest
d o c umented duration of complete cytogenetic re m i s s i o n
was 9 months (patients 1 and 10). There was no correlation
Table 1. Patient characteristics
Age Disease phase Disease duration INF duration HU duration
Patient (y) Sex (mo) (mo) (mo)/response (mo)
1 17 M CP 30 14B 5
2 44 M AP* 26 4/A 5
3 46 M AP* † 72 15/B 1, Bu (7)
4 54 F CP 51 6/B 40
5 46 M AP* 17 12/B 0
6 56 F AP* 26 25/B 0
7 53 M AP* 18 7/B 0
8 43 F CP 24 6/B 19
9 50 F CP 13 6/B 6
10 44 M CP 23 12/A 0
11 40 M CP 19 6/B 14
12 45 F CP 27 6/B 21
13 32 M CP 25 5/A 7
A, hemotologic remission not achieved; AP, accelerated phase; B, no cytogenetic response; Bu, busulfan; CP, chronic phase; HU, hydroxyurea; INF, interferon.
*Additional chromosomal abnormalities.
†Progressive disease.
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between duration of disease (r 5 0.06, p 5 0.86) or inter-
f e ron use (r 5 0.23, p 5 0.46) and time to cytogenetic
relapse. Three patients (patients 2, 10, and 12) have experi-
enced a hematologic relapse (Table 2). At relapse, GM-CSF
was given to four patients: patients 6, 8, and 9 at cytogenetic
relapse and patient 10 at hematologic relapse. Although
t h ree patients showed no cytogenetic response to 5–9
months of GM-CSF treatment, patient 10 has entered a
complete hematologic and a partial cytogenetic (50% Ph–)
remission after 2 months of GM-CSF treatment (Table 2).
Interferon has been started in three patients, two of whom
had failed GM-CSF. Patients who are resistant to interferon
b e f o re transplant can become interf e ron-sensitive [26,27]:
patients 8 and 11 have had a 50% reduction in their Ph1
metaphases due to reinstitution of interf e ro n -a ( Table 2).
Nine patients are still alive with a median follow-up of 18
months (range 12–32 months), and all but one are in a
hematologic remission (Table 2). 
DISCUSSION
Initial engraftment in most patients in previous studies of
autologous BMT for CML has been partially or completely
P h1 [2–8]. Recently, Carella et al. re p o rted complete Ph–
engraftment in a high percentage (53%) of patients who had
u n d e rgone mobilized peripheral blood autografting for CML
[28]. Engraftment was substantially more rapid (a median of
13 days to an ANC of 500/mm3) than in our patients. How-
e v e r, most of the patients in the trial were in early (#6 m o n t h s )
C P, none had previously received interf e ron, and those whose
mobilized autografts contained a high level of Ph1 cells were
excluded [28]. Furt h e r, the median time to Ph1 re c u rre n c e
was 5 months, even though all patients were receiving inter-
f e ro n -a after transplantation [28]. Our results of nine of
10 evaluable patients achieving 100% Ph– engraftment are
p a rticularly intriguing because of the high-risk features of the
patients enrolled in the study: five patients were in AP,
median duration of disease before transplantation was
24 months [29], and only patients who failed to achieve a
cytogenetic response to interf e ron were eligible. 
Both autograft purging and systemic antileukemic activ-
ity beyond that provided by the cytotoxic preparative re g i-
men are needed for autologous BMT to be successful in
CML. Thus, in this trial we combined autograft purg i n g
with post-transplant GM-CSF, approaches that were both
based on our preclinical studies. The relative roles of CCE,
the incubation of the autograft in GM-CSF, and the post-
transplantation GM-CSF in producing the cytogenetic
responses are unclear. More o v e r, we cannot determ i n e
whether relapse resulted from a failure of the autograft
manipulation or a failure of systemic GM-CSF or both.
N e v e rtheless, the consistent 100% Ph– engraftment in our
trial suggests that the clinical purging was effective. It is
likely that initial engraftment with Ph1 hematopoiesis re s u l t s
f rom CML progenitors contaminating the autograft, because
patients undergoing syngeneic BMT for CML universally
engraft with 100% Ph– hematopoiesis even when they even-
tually relapse. In addition, genetic marking studies demon-
strate that autografts contaminated with Ph1 p rogenitor cells
contribute to relapse [9]. Our graft manipulation (isolation of
small-sized cells [20] and a 3-day incubation in GM-CSF
[21]) had little effect on the percentage of Ph1 metaphases in
the autograft, bringing into question its effectiveness. How-
e v e r, cytogenetic analysis likely measures committed pro-
genitors and is not an accurate re flection of the presence of
n o rmal and CML progenitors with long-term pro l i f e r a t i v e
potential. This limitation of cytogenetic analysis is illustrated
by the fact that patients transplanted with 100% Ph– a u t o-
grafts frequently engraft with Ph1 hematopoiesis [8,28]. 
The mechanism responsible for the c linica l
antileukemic effect of allogeneic T cells, which is absent
with autologous BMT, remains unclear. It is generally
assumed that the antileukemic activity of allogeneic T cells
results from a cytotoxic effect related to GVHD. However,
the development of GVHD appears to have either little
[10] or no [30] influence on relapse after allogeneic BMT
Table 2. BMT results
%Ph 1 (PCR)
Days to ANC Days to last (mo after BMT) Time to Ph 1 Treatment Current status
Patient .500/ mL platelet transfusion 1–2 3 6 (mo) after relapse (mo)
1 31 33 0 (PCR 2)        ND (ND) 0 (PCR 2) 22 None HCR, 100% Ph 1 (32)
2 44 — 0 (PCR 2) 100 (ND) — 4 — Died day 148, blast crisis
3 — — — — — — — Died day 134, graft failure
4 180 210 0 (PCR 2) 0 (PCR 1) 10 6 None HCR, 100% Ph 1 (27)
5 — — — — — — — Died day 15, VOD
6 35 210 0 (PCR 1) 0 (ND) 10 6 GM-CSF HCR, 100% Ph 1 (21)
7 — — — — — — — Died day 72, graft failure
8 20 22 0 (PCR 2) 3 30 6 GM-CSF/INF HCR, 50% Ph 1 on INF (18)
9 22 81 0 (PCR 2) 0 (ND) 55 6 GM-CSF/INF HCR, 90% Ph 1 on INF (18)
10 24 120 0 (PCR 2) 5 (ND) 0 (PCR 2) 12 GM-CSF HCR, 50% Ph 1 on GM-CSF (17)
11 19 35 5 (ND) 0 (PCR 2) 85 6 INF HCR, 50% Ph 1 on INF (18)
12 123 129 ND (ND) 60 100 3 None CP (13)
13 32 30 0 (PCR 2) 0 (ND) 70 6 None HCR, 80% Ph 1 (12)
ANC, absolute neutrophil count; BMT, bone marrow transplantation; CP, chronic phase; GM-CSF, granulocyte-macrophage colony-stimulating factor; HCR,
hematologic complete remission; INF, interferon; ND, not done; PCR, polymerase chain reaction; Ph, Philadelphia chromosome; VOD, veno-occlusive disease. 
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for CML. More o v e r, the potent antileukemic effect of
donor lymphocyte infusions in CML patients who have
relapsed after allogeneic BMT can occur in the absence of
clinical GVHD [13]. Another possible component of the
allogeneic T-cell–mediated effect against CML is thro u g h
the production of growth factors that eradicate re s i d u a l
CML progenitors by inducing their terminal diff e re n t i a-
tion [21,22]. Conversely, low levels of growth factors may
allow the leukemic clone to escape terminal diff e re n t i a t i o n .
G rowth factor levels, in fact, are reduced in chronic phase
CML patients [31]. T-cell depletion, which is associated
with a high risk of relapse in CML, also blunts the high
g rowth factor levels [32] that normally occur after BMT
[32–34]. Thus, growth factor levels may be a critical
d e t e rminant of whether CML cells survive in vivo as well
as in v i t ro [ 2 1 ] .
Two patients in AP who received transplants failed to
achieve engraftment; one of these patients also received the
“back-up” autograft. Graft failure is not uncommon with
unmanipulated autografts for transformed CML [35].
Moreover, it is difficult to isolate normal hematopoietic pro-
genitors from patients with advanced stage CML [6,36].
Thus, bone marrow from advanced stage CML patients may
lack sufficient numbers of normal progenitors to pro d u c e
engraftment. 
The ability to produce consistent 100% Ph– e n g r a f t-
ment, especially in a group of patients with high-risk feature s
( A P, long disease duration [29], or no cytogenetic response to
i n t e rf e ron), is encouraging for the future use of autologous
BMT in CML. The results of this trial also suggest that
GM-CSF provides a clinically important antileukemic eff e c t
in CML, similar to its activity in vitro [21,22]. Providing fur-
ther evidence of the clinical activity of GM-CSF against
CML, one patient has achieved at least a partial cytogenetic
remission even though the GM-CSF was started after hema-
tologic relapse. The mechanism for the antileukemic activity
of GM-CSF against CML is unclear. Although our p re c l i n i-
cal studies suggest GM-CSF induces terminal diff e re n t i a-
tion of CML progenitors, the potent in vivo i m m u n o m o d u-
l a ry effects of GM-CSF [37,38] may also contribute to an
antileukemic effect. 
GM-CSF was given for 2 months after BMT in this
trial. However, it is not unusual to detect CML for up to 6
months after allogeneic BMT in patients who are cure d
[39]. This could signify an ongoing allogeneic antileukemic
e ffect against CML progenitors. There f o re, our new trial
incorporates 6 months of GM-CSF as systemic antileukemic
therapy against CML after autologous BMT, in an attempt
to increase the duration of the cytogenetic remission. 
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